Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, Hyun JW, Oliveira LM, Reindl M, Seifert-Held T, Sepulveda M, Siritho S, Waters PJ, Kurosawa K, Akaishi T, Kuroda H, Misu T, Prayoonwiwat N, Berger T, Saiz A, Kim HJ, Nomura K, Callegaro D, Fujihara K, Aoki M. Kaneko K, et al. Among authors: nomura k. J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1257-1259. doi: 10.1136/jnnp-2015-312676. Epub 2016 Jan 22. J Neurol Neurosurg Psychiatry. 2016. PMID: 26800711 No abstract available.
CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, Nishiyama S, Takahashi T, Misu T, Kuroda H, Tanaka S, Nomura K, Hashimoto Y, Callegaro D, Steinman L, Fujihara K, Aoki M. Kaneko K, et al. Among authors: nomura k. J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):927-936. doi: 10.1136/jnnp-2018-317969. Epub 2018 Jun 6. J Neurol Neurosurg Psychiatry. 2018. PMID: 29875186 Free PMC article.
The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement.
Sugimoto K, Mori M, Liu J, Tanaka S, Kaneko K, Oji S, Takahashi T, Uzawa A, Uchida T, Masuda H, Ohtani R, Nomura K, Hiwasa T, Kuwabara S. Sugimoto K, et al. Among authors: nomura k. J Neuroimmunol. 2019 Nov 15;336:577021. doi: 10.1016/j.jneuroim.2019.577021. Epub 2019 Aug 21. J Neuroimmunol. 2019. PMID: 31473520
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Among authors: nomura k. Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199095 Clinical Trial.
Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany.
Liu J, Mori M, Zimmermann H, Brandt A, Havla J, Tanaka S, Sugimoto K, Oji S, Uzawa A, Asseyer S, Cooper G, Jarius S, Bellmann-Strobl J, Ruprecht K, Siebert N, Masuda H, Uchida T, Ohtani R, Nomura K, Meinl E, Kuempfel T, Paul F, Kuwabara S. Liu J, et al. Among authors: nomura k. J Neurol Neurosurg Psychiatry. 2020 Nov 20:jnnp-2020-324422. doi: 10.1136/jnnp-2020-324422. Online ahead of print. J Neurol Neurosurg Psychiatry. 2020. PMID: 33219036
Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.
Tahara M, Oeda T, Okada K, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Among authors: nomura k. Mult Scler Relat Disord. 2022 Apr;60:103730. doi: 10.1016/j.msard.2022.103730. Epub 2022 Mar 7. Mult Scler Relat Disord. 2022. PMID: 35287025 Free article. Clinical Trial.
2,404 results